Company intelligence / Profile preview
Jilin Aodong Yanbian Pharmaceutical
- Ownership
- Private
- Development stage
- Other
Overview
Jilin Aodong Yanbian Pharmaceutical markets approved products for diabetes mellitus and chronic hepatitis B in China, focuses on traditional Chinese medicines and small molecules, and shows a track record of regulatory approvals and commercial activity.[5][8]
- Therapeutic areas
- Infectious DiseasesEndocrinology
- Modalities
- Herbal medicineSmall molecule
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Jilin Aodong Yanbian Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jilin Aodong Yanbian Pharmaceutical.